A number of clinical/disease areas have been prioritised by the Technology Strategy Board (TSB) and Department of Health (DH) for the DIIA Innovation Platform. To support commissioning of technology development for detection of hospital acquired infections (HAIs) in humans, a scoping review has been undertaken to help identify the specific requirements for new diagnostic test development and likely economic payback for point of care (POC) tests for HAIs in the UK.
This report presents economic analysis findings for the following HAIs:
- Methicillin-resistant Staphylococcus aureus (MRSA)
- Clostridium difficile (C. difficile)
- Extended-spectrum beta-lactamase (ESBL) infections
